Abstract
BackgroundOver the past 130 years, the field of immunotherapy has progressed to the use of cytokines and of immune checkpoint inhibitors, namely anti-PD-1 and anti-CTLA4. Despite these advances, response rates...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
